Saltz, J
Martin Holst Lange, Executive Vice President for Development at Novo Nordisk, stated, These data reinforce the comprehensive set of health benefits of semaglutide, making it a strong option for healthcare professionals addressing the spectrum of metabolic and cardiovascular health. The SOUL trial confirmed the established safety and tolerability of oral semaglutide, with no new safety concerns identified and long-term safety data covering over 33 million patient years
Our findings, combined with the prior report from Qiu et al
Regional Segment Analysis of the Global Glutathione Market North America (U.S., Canada, Mexico) Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and the Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA) North America is anticipated to hold the largest share of the global glutathione market over the predicted timeframe
Of these 50 WEGOVY-treated patients, 28 patients (2% of the total WEGOVY-treated study population) developed antibodies that cross-reacted with native GLP-1
/assets/images/provider/photos/2775923.jpeg)
